% | $
Quotes you view appear here for quick access.

BG Medicine, Inc. Message Board

  • darthnvader darthnvader Jan 2, 2013 4:09 PM Flag

    BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

    WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3(R) blood test has obtained a CE Mark, an important step in the company's commercial strategy.

    The BGM Galectin-3 test will be distributed through bioMerieux's VIDAS(R) immunoassay platform which includes about 27,000 installed instruments worldwide. bioMerieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMerieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.

    "The BGM Galectin-3 test has the potential to play a major role in improving the management of heart failure," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "The launch of the first automated version of our test is a watershed and exciting moment for our company. Through its broad CE-marked installed base, bioMerieux is in a position to drive the adoption of the test in Europe. Offering an automated version of the galectin-3 assay is critical for us to obtain broad-based and rapid global adoption. Partnering with bioMerieux, as well as Abbott, Alere and Siemens provides BG Medicine tremendous international coverage to drive commercial adoption over the next several years."

    The CE Mark for bioMerieux's automated version of the BGM Galectin-3 test is the latest in a series of steps designed to further BG Medicine's three-pillared business model for the test, which is focused on rapid commercial adoption driven by sales through automated partners, specialized labs and the targeting of US hospitals with high readmissions rates. Recent developments in this commercial strategy have included:

    The launch of a major campaign to grow BGM Galectin-3 test sales in hospital settings. BG Medicine launched a new campaign in November 2012 focused on the urgent need to reduce rates of unplanned hospital readmissions. The Centers for Medicare & Medicaid Services (CMS) guidelines that went into effect on October 1, 2012 will result in new financial penalties expected to reach an aggregate of nearly $300 million in 2013 and nearly $1 billion by 2015, if improvements are not made. Because heart failure patients with elevated levels of galectin-3 are two-to-three times more likely than other heart failure patients to be readmitted to the hospital within 30 days of discharge, the company believes that identifying and risk-stratifying these high-risk patients through galectin-3 testing is a potentially valuable and cost-effective tool in a hospital's strategy to reduce unplanned 30-day readmissions. The company expects this initiative will accelerate the sales ramp-up and the widespread adoption of galectin-3 testing.
    The conversion of a medical liaison organization to a US-based sales organization. BG Medicine is transforming its current field force from an awareness- and education-focused organization into one with a sales mission and growth strategy. The field force will focus initially on promoting galectin-3 testing at a core set of hospitals with higher-than-average readmission rates, which are at risk of incurring significant financial penalties due to new rules affecting readmissions set by CMS.
    The opening of a CLIA (Clinical Laboratory Improvement Amendments) certified clinical laboratory. BG Medicine expects to open the BG Medicine CLIA laboratory in the first half of 2013 in order to make galectin-3 testing available to more hospitals and other health care providers. The company expects this CLIA lab will further strengthen the company's own infrastructure to support sales made directly by BG Medicine.

    "2013 is poised to be a year of great progress in our commercial strategy for the manual and automated versions of the BGM Galectin-3 test and we are pleased to begin the year with this important development in the execution of this strategy," continued Mr. Bouvier.

    About Galectin-3 and Heart Failure

    Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to carbohydrates called beta-galactosides. Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure, and is believed to be a primary mediator of progressive cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and adverse remodeling (changes in the structure of the heart). Higher levels of galectin-3 are associated with a more aggressive form of heart failure and 30% or more of mild to moderate heart failure patients will have elevated levels of galectin-3. Heart failure affects an estimated 5.8 million Americans, with approximately 670,000 new cases occurring each year. The direct and indirect cost of heart failure in the United States for 2010 is estimated to be $39.2 billion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.11+0.01(+10.85%)Oct 26 1:49 PMEDT